Last reviewed · How we verify
Imodium Multi-Symptom Relief — Competitive Intelligence Brief
marketed
dimethicone
Dermatology
Live · refreshed every 30 min
Target snapshot
Imodium Multi-Symptom Relief (DIMETHICONE) — Mcneil.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Imodium Multi-Symptom Relief TARGET | DIMETHICONE | Mcneil | marketed | dimethicone | 1997-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (dimethicone class)
- Mcneil · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Imodium Multi-Symptom Relief CI watch — RSS
- Imodium Multi-Symptom Relief CI watch — Atom
- Imodium Multi-Symptom Relief CI watch — JSON
- Imodium Multi-Symptom Relief alone — RSS
- Whole dimethicone class — RSS
Cite this brief
Drug Landscape (2026). Imodium Multi-Symptom Relief — Competitive Intelligence Brief. https://druglandscape.com/ci/dimethicone. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab